Pliant Therapeutics Provides Corporate Update and Reports Fi

BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring...

Related Keywords

Australia , Massachusetts , United States , Christopher Keenan , Bernard Coulie , European Union , Oxford Finance , Corporate Communications , Youtube , Drug Administration , Linkedin , Pliant Therapeutics Inc , Novartis , Australia Research Ethics Committee , Nasdaq , Facebook , European Medicines Agency , Chief Executive Officer , Massachusetts General , Enhanced Liver Fibrosis , Research Ethics Committee , Pliant Therapeutics , Fast Track Designation , Orphan Drug Designation , Private Securities Litigation Reform Act , Financial Condition , Quarterly Report , Media Contact , Investor Relations , Months Ended March , Markets ,